- Home
- SHPH vs SLRX Comparison
SHPH vs SLRX Comparison
Compare SHPH & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHPH
- SLRX
- Stock Information
- Founded
- SHPH 2012
- SLRX N/A
- Country
- SHPH United States
- SLRX United States
- Employees
- SHPH N/A
- SLRX N/A
- Industry
- SHPH Biotechnology: Pharmaceutical Preparations
- SLRX Biotechnology: Pharmaceutical Preparations
- Sector
- SHPH Health Care
- SLRX Health Care
- Exchange
- SHPH Nasdaq
- SLRX Nasdaq
- Market Cap
- SHPH 3.2M
- SLRX 3.6M
- IPO Year
- SHPH 2022
- SLRX N/A
- Fundamental
- Price
- SHPH $2.55
- SLRX $0.97
- Analyst Decision
- SHPH
- SLRX
- Analyst Count
- SHPH 0
- SLRX 0
- Target Price
- SHPH N/A
- SLRX N/A
- AVG Volume (30 Days)
- SHPH 356.7K
- SLRX 522.9K
- Earning Date
- SHPH 11-13-2025
- SLRX 11-10-2025
- Dividend Yield
- SHPH N/A
- SLRX N/A
- EPS Growth
- SHPH N/A
- SLRX N/A
- EPS
- SHPH N/A
- SLRX N/A
- Revenue
- SHPH N/A
- SLRX N/A
- Revenue This Year
- SHPH N/A
- SLRX N/A
- Revenue Next Year
- SHPH N/A
- SLRX N/A
- P/E Ratio
- SHPH N/A
- SLRX N/A
- Revenue Growth
- SHPH N/A
- SLRX N/A
- 52 Week Low
- SHPH $2.25
- SLRX $0.91
- 52 Week High
- SHPH $30.84
- SLRX $108.00
- Technical
- Relative Strength Index (RSI)
- SHPH 32.85
- SLRX 18.32
- Support Level
- SHPH $2.25
- SLRX $3.55
- Resistance Level
- SHPH $3.56
- SLRX $3.20
- Average True Range (ATR)
- SHPH 0.22
- SLRX 0.39
- MACD
- SHPH -0.06
- SLRX -0.27
- Stochastic Oscillator
- SHPH 21.64
- SLRX 2.32
About SHPH Shuttle Pharmaceuticals Holdings Inc.
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. It is developing a pipeline of products designed to address the limitations of the current cancer therapies as well as to extend to the new applications of RT. The company believes that its product candidates will enable the company to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.